List of Tables
    Table 1. Immune Thrombocytopenia Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Immune Thrombocytopenia Treatment Market Trends
    Table 3. Immune Thrombocytopenia Treatment Market Drivers
    Table 4. Immune Thrombocytopenia Treatment Market Challenges
    Table 5. Immune Thrombocytopenia Treatment Market Restraints
    Table 6. Global Immune Thrombocytopenia Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Immune Thrombocytopenia Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Immune Thrombocytopenia Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Immune Thrombocytopenia Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Immune Thrombocytopenia Treatment Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Immune Thrombocytopenia Treatment Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Immune Thrombocytopenia Treatment Revenue Share by Player, 2017-2022
    Table 13. Global Immune Thrombocytopenia Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Immune Thrombocytopenia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2021)
    Table 15. Top Players of Immune Thrombocytopenia Treatment in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Immune Thrombocytopenia Treatment Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Immune Thrombocytopenia Treatment Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Immune Thrombocytopenia Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Immune Thrombocytopenia Treatment Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Immune Thrombocytopenia Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Immune Thrombocytopenia Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Immune Thrombocytopenia Treatment Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Immune Thrombocytopenia Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Immune Thrombocytopenia Treatment Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Immune Thrombocytopenia Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Immune Thrombocytopenia Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Immune Thrombocytopenia Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. CSL Behring Company Details
    Table 31. CSL Behring Business Overview
    Table 32. CSL Behring Immune Thrombocytopenia Treatment Product
    Table 33. CSL Behring Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 34. CSL Behring Recent Development
    Table 35. Amgen Company Details
    Table 36. Amgen Business Overview
    Table 37. Amgen Immune Thrombocytopenia Treatment Product
    Table 38. Amgen Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 39. Amgen Recent Development
    Table 40. F.Hoffmann-La Roche Company Details
    Table 41. F.Hoffmann-La Roche Business Overview
    Table 42. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Product
    Table 43. F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 44. F.Hoffmann-La Roche Recent Development
    Table 45. Kyowa Hakko Kirin Company Details
    Table 46. Kyowa Hakko Kirin Business Overview
    Table 47. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Product
    Table 48. Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 49. Kyowa Hakko Kirin Recent Development
    Table 50. Rigel Pharmaceuticals Company Details
    Table 51. Rigel Pharmaceuticals Business Overview
    Table 52. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Product
    Table 53. Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 54. Rigel Pharmaceuticals Recent Development
    Table 55. Shionogi Company Details
    Table 56. Shionogi Business Overview
    Table 57. Shionogi Immune Thrombocytopenia Treatment Product
    Table 58. Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 59. Shionogi Recent Development
    Table 60. Dova Pharmaceuticals Company Details
    Table 61. Dova Pharmaceuticals Business Overview
    Table 62. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Product
    Table 63. Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 64. Dova Pharmaceuticals Recent Development
    Table 65. Novartis Company Details
    Table 66. Novartis Business Overview
    Table 67. Novartis Immune Thrombocytopenia Treatment Product
    Table 68. Novartis Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 69. Novartis Recent Development
    Table 70. Shire Company Details
    Table 71. Shire Business Overview
    Table 72. Shire Immune Thrombocytopenia Treatment Product
    Table 73. Shire Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 74. Shire Recent Development
    Table 75. Ligand Pharmaceuticals Company Details
    Table 76. Ligand Pharmaceuticals Business Overview
    Table 77. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Product
    Table 78. Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 79. Ligand Pharmaceuticals Recent Development
    Table 80. GSK Company Details
    Table 81. GSK Business Overview
    Table 82. GSK Immune Thrombocytopenia Treatment Product
    Table 83. GSK Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 84. GSK Recent Development
    Table 85. Grifols Biologicals Company Details
    Table 86. Grifols Biologicals Business Overview
    Table 87. Grifols Biologicals Immune Thrombocytopenia Treatment Product
    Table 88. Grifols Biologicals Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 89. Grifols Biologicals Recent Development
    Table 90. Jiangsu Hengrui Pharmaceutical Company Details
    Table 91. Jiangsu Hengrui Pharmaceutical Business Overview
    Table 92. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Product
    Table 93. Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2017-2022) & (US$ Million)
    Table 94. Jiangsu Hengrui Pharmaceutical Recent Development
    Table 95. Research Programs/Design for This Report
    Table 96. Key Data Information from Secondary Sources
    Table 97. Key Data Information from Primary Sources
List of Figures
    Figure 1. Immune Thrombocytopenia Treatment Product Picture
    Figure 2. Global Immune Thrombocytopenia Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Immune Thrombocytopenia Treatment Market Size 2017-2028 (US$ Million)
    Figure 4. United States Immune Thrombocytopenia Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Immune Thrombocytopenia Treatment Market Size 2017-2028 (US$ Million)
    Figure 6. United States Immune Thrombocytopenia Treatment Market Share in Global 2017-2028
    Figure 7. Immune Thrombocytopenia Treatment Report Years Considered
    Figure 8. Product Picture of Corticosteroids
    Figure 9. Product Picture of Intravenous Immunoglobulin (IVIG)
    Figure 10. Product Picture of Anti-D Immunoglobulin
    Figure 11. Product Picture of Thrombopoietin Receptor Agonist (TPO-RA)
    Figure 12. Product Picture of Others
    Figure 13. Global Immune Thrombocytopenia Treatment Market Share by Type in 2022 & 2028
    Figure 14. Global Immune Thrombocytopenia Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
    Figure 16. United States Immune Thrombocytopenia Treatment Market Share by Type in 2022 & 2028
    Figure 17. United States Immune Thrombocytopenia Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Immune Thrombocytopenia Treatment Market Share by Type (2017-2028)
    Figure 19. Product Picture of Hospitals and Clinics
    Figure 20. Product Picture of Research and Academic Institutes
    Figure 21. Product Picture of Others
    Figure 22. Global Immune Thrombocytopenia Treatment Market Share by Application in 2022 & 2028
    Figure 23. Global Immune Thrombocytopenia Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. Global Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
    Figure 25. United States Immune Thrombocytopenia Treatment Market Share by Application in 2022 & 2028
    Figure 26. United States Immune Thrombocytopenia Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 27. United States Immune Thrombocytopenia Treatment Market Share by Application (2017-2028)
    Figure 28. North America Immune Thrombocytopenia Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. U.S. Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Canada Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Europe Immune Thrombocytopenia Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 32. Germany Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. France Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. U.K. Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Italy Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Russia Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Immune Thrombocytopenia Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 38. China Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Japan Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. South Korea Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. India Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Australia Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Taiwan Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Indonesia Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Thailand Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Malaysia Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Philippines Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Latin America Immune Thrombocytopenia Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Mexico Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Brazil Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Argentina Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Immune Thrombocytopenia Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Turkey Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. U.A.E Immune Thrombocytopenia Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. CSL Behring Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 57. Amgen Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 58. F.Hoffmann-La Roche Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 59. Kyowa Hakko Kirin Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 60. Rigel Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 61. Shionogi Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 62. Dova Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 63. Novartis Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 64. Shire Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 65. Ligand Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 66. GSK Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 67. Grifols Biologicals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 68. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2017-2022)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed